Metabolite Safety in Drug Development
(Sprache: Englisch)
A reference on drug metabolism and metabolite safety in the development phase, this book reviews the analytical techniques and experimental designs critical for metabolite studies. It features case studies of lessons learned and real world examples, along...
Leider schon ausverkauft
versandkostenfrei
Buch (Gebunden)
135.00 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Metabolite Safety in Drug Development “
Klappentext zu „Metabolite Safety in Drug Development “
A reference on drug metabolism and metabolite safety in the development phase, this book reviews the analytical techniques and experimental designs critical for metabolite studies. It features case studies of lessons learned and real world examples, along with regulatory perspectives from the US FDA and EMA.* Reviews the analytical techniques and experimental designs critical for metabolite studies
* Covers methods including chirality, species differences, mass spectrometry, radiolabels, and in vitro / in vivo correlation
* Discusses target pharmacology, in vitro systems aligned to toxicity tests, and drug-drug interactions
* Includes perspectives from authors with firsthand involvement in industry and the study of drug metabolites, including viewpoints that have influenced regulatory guidelines
Inhaltsverzeichnis zu „Metabolite Safety in Drug Development “
Preface xiList of Contributors xiii
1 Introduction: History of Metabolite Safety in Drug Development 1
Dennis A. Smith and Suzanne L. Iverson
1.1 People, Events, and Reaction, 1
1.2 The Rise of Industrial Drug Metabolism, 2
1.3 The Appearance of Mist, 4
1.4 The Journey Triggered by Thalidomide: Would Present Science have Made a Difference?, 5
1.5 Key Events from Thalidomide to Mist, 8
1.6 The Purpose of this Book, 13
References, 14
2 "Mist" and other Metabolite Guidelines in the Context of Industrial Drug Metabolism 17
Gordon J. Dear and Angus N. R. Nedderman
2.1 A Historical Perspective, 17
2.2 The Emergence of the Regulatory Guidance Documents, 23
2.3 Impact of the Guidelines, 30
2.4 Future Directions, 32
References, 37
3 Metabolite Technology: Qualitative and Quantitative 45
Gordon J. Dear and Andrew McEwen
3.1 Introduction, 45
3.2 Clinical Samples, 46
3.3 Preclinical Samples, 48
3.4 Radiolabeled Test Compounds, 51
3.5 Mass Spectrometry, 55
3.6 NMR Spectroscopy, 65
3.7 Accelerator Mass Spectrometry, 72
References, 75
Further Reading, 85
4 In Vitro Methods for Evaluation of Drug Metabolism: Identification of Active and Inactive Metabolites and the Enzymes that Generate them 87
R. Scott Obach, Amit S. Kalgutkar, and Deepak K. Dalvie
4.1 Introduction, 87
4.2 In Vitro Methods for Metabolite Profiling and Identification, 88
4.2.1 In Vitro Systems We Use: Most Complex to Simplest, 88
4.2.2 Criteria for Selecting the Most Appropriate In Vitro System for In Vitro Metabolite Profiling, 92
4.3 Application of In Vitro Methods for Metabolite Profiling in Drug Discovery and Development, 96
4.3.1 In Vitro Metabolite Profiling and Identification in the Early Drug Discovery Stage,
... mehr
96
4.3.2 In Vitro Metabolite Profiling and Identification in the Late Drug Discovery Stage: Selection of Candidate Compounds for Further Development, 98
4.3.3 In Vitro Metabolite Profiling and Identification in the Drug Development Stage: Support of Candidate
Compounds for New Drug Registration, 101
4.4 How Well Do In Vitro Metabolite Profiles Represent In Vivo Metabolite Profiles?, 103
4.5 Pharmacologically Active Metabolites and their Identification, 104
4.5.1 When Is a Metabolite Considered Active?, 104
4.5.2 Experimental Approaches to Reveal Active Metabolites, 106
4.6 Conclusion, 108
References, 108
5 Integrated Reactive Metabolite Strategies 111
J. Gerry Kenna and Richard A. Thompson
5.1 Introduction, 111
5.2 Role of RMs in Toxicity, 114
5.3 Strategies for Predicting, Assessing, and Derisking RM-Mediated Toxicity, 118
5.3.1 Assessing RM Hazard: Awareness/Avoidance, 118
5.3.2 Assessing RM Risk: Covalent Binding and Dose, 122
5.3.3 Integrated Risk Assessments: Integrating RM Assessment and In Vitro Safety Assay Endpoints, 127
5.3.4 Integrated RM Risk Assessments: Future Directions, 129
References, 131
6 Understanding Drug Metabolism in Humans: In Vivo 141
Lars Weidolf and Ian D. Wilson
6.1 Introduction, 141
6.2 Preclinical Animal Studies, 142
6.2.1 Whole-Body Autoradiography and Imaging, 144
6.3 Early Human In Vivo Metabolism Studies, 146
6.3.1 Pre-FTIM Data Acquisition, 147
6.3.2 The First Clinical Studies, 149
6.3.3 Metabolite Exposure Assessment, 150
6.3.4 Exceptions to Regulatory Recommendation
4.3.2 In Vitro Metabolite Profiling and Identification in the Late Drug Discovery Stage: Selection of Candidate Compounds for Further Development, 98
4.3.3 In Vitro Metabolite Profiling and Identification in the Drug Development Stage: Support of Candidate
Compounds for New Drug Registration, 101
4.4 How Well Do In Vitro Metabolite Profiles Represent In Vivo Metabolite Profiles?, 103
4.5 Pharmacologically Active Metabolites and their Identification, 104
4.5.1 When Is a Metabolite Considered Active?, 104
4.5.2 Experimental Approaches to Reveal Active Metabolites, 106
4.6 Conclusion, 108
References, 108
5 Integrated Reactive Metabolite Strategies 111
J. Gerry Kenna and Richard A. Thompson
5.1 Introduction, 111
5.2 Role of RMs in Toxicity, 114
5.3 Strategies for Predicting, Assessing, and Derisking RM-Mediated Toxicity, 118
5.3.1 Assessing RM Hazard: Awareness/Avoidance, 118
5.3.2 Assessing RM Risk: Covalent Binding and Dose, 122
5.3.3 Integrated Risk Assessments: Integrating RM Assessment and In Vitro Safety Assay Endpoints, 127
5.3.4 Integrated RM Risk Assessments: Future Directions, 129
References, 131
6 Understanding Drug Metabolism in Humans: In Vivo 141
Lars Weidolf and Ian D. Wilson
6.1 Introduction, 141
6.2 Preclinical Animal Studies, 142
6.2.1 Whole-Body Autoradiography and Imaging, 144
6.3 Early Human In Vivo Metabolism Studies, 146
6.3.1 Pre-FTIM Data Acquisition, 147
6.3.2 The First Clinical Studies, 149
6.3.3 Metabolite Exposure Assessment, 150
6.3.4 Exceptions to Regulatory Recommendation
... weniger
Autoren-Porträt
Suzanne L. Iverson, PhD, ERT, earned her PhD studying reactive drug metabolites and idiosyncratic drug reactions (University of Toronto, Dr. Jack Uetrecht supervisor) and has worked in the pharmaceutical industry for over 14 years as principal scientist and manager of development in vitro/in vivo metabolism and distribution imaging as well as functional project leader for both DMPK and safety assessment functions. Since 2011, she has served on the management committee of the Drug Metabolism Discussion Group, UK, and the Board of the PK-Metabolism subcommittee of the Swedish Pharmaceutical Society.Dennis A. Smith, PhD, currently holds part-time advisory and academic positions and, previously, worked in the pharmaceutical industry for 32 years. He has coauthored over 150 publications, including Attrition in the Pharmaceutical Industry (Wiley, 2016), Reactive Drug Metabolites (Wiley, 2012), and three editions of the book Pharmacokinetics and Metabolism in Drug Design (Wiley, 2012).
Bibliographische Angaben
- 2016, 1. Auflage, 352 Seiten, Maße: 24,2 cm, Gebunden, Englisch
- Herausgegeben: Suzanne L. Iverson, Dennis A. Smith
- Verlag: Wiley & Sons
- ISBN-10: 111894965X
- ISBN-13: 9781118949658
Sprache:
Englisch
Kommentar zu "Metabolite Safety in Drug Development"
0 Gebrauchte Artikel zu „Metabolite Safety in Drug Development“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Metabolite Safety in Drug Development".
Kommentar verfassen